Immunity to poliomyelitis in The Netherlands.

Despite a vaccination coverage rate of 97%, several poliomyelitis outbreaks occurred in the Netherlands during the last three decades, all among sociogeographically clustered, unvaccinated persons. Therefore, to eradicate polio, insight into poliomyelitis immunity is particularly useful. In 1995-1996, the authors conducted a population-based study and determined neutralizing antibodies against poliovirus types 1, 2, and 3 in 9,274 sera from the general population and from religious groups rejecting vaccination.

IPV-Vero vaccine induces a strong booster reaction and is well tolerated in adults.

A phase 1-2 trial was conducted in 48 adults to study safety and immunogenicity of an inactivated poliovirus vaccine produced using Vero cells (IPV-Vero). Participants received 2 intramuscular injections with IPV-Vero (40-8-32 D-Ag units) 4 weeks apart. IPV-Vero was well tolerated, and induced strong antibody responses in all participants.